North Carolina State University

Dupont Nutrition Biosciences Aps

Lifeedit Therapeutics, Inc.

Danisco A/s

Rodolphe Barrangou

Michael W Lassner

Dennis A Romero

Todd Robert Klaenhammer

Mark R Moore

Philippe Horvath

Christophe Fremaux

Alexandra Briner Crawley

W Michael Russell

Patrick Boyaval

Eric Altermann

Tri Duong

Tedd D Elich

Tyson D Bowen

Michael Coyle

Claudio Hidalgo Cantabrana

Kurt M Selle

Alexandra E Briner

Nina Rautonen

Sampo Lahtinen

Kirsti Tiihonen

Heli Putaala

Pierre Desreumaux

Didier Carcano

Claudio Hidalgo-Cantabrana

Eric R Altermann

Andrea Azcarate-Peril

Phillippe Horvath

Rémy Burcelin

Remy Burcelin

Lindsay L Traeger

Jan-Peter Van Pijkeren

Dennis Romero

Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.

RNA-guided nucleases and active fragments and variants thereof and methods of use

This invention is directed to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays and recombinant nucleic acid constructs encoding Type 1-E CASCADE complexes, plasmids, retroviruses and bacteriophage comprising the same, and methods of use thereof for modifying genomes and expression. Further disclosed are methods of modifying (editing) the genome of target organisms using the constructs.

Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression

This invention relates to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays and recombinant nucleic acid constructs encoding Type I-E CASCADE complexes, plasmids, retroviruses and bacteriophage comprising the same, and methods of use thereof for killing one or more cells in a population of bacterial and/or archaeal cells.

Recombinant type I CRISPR-Cas system and uses thereof for killing target cells

This invention relates to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays and recombinant nucleic acid constructs encoding Type I-E CASCADE complexes, plasmids, retroviruses and bacteriophage comprising the same, and methods of use thereof for screening for variant cells of an organism.

Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells

The present invention is directed to methods and compositions comprising novel CRISPR polypeptides and polynucleotides for site-specific cleavage and nicking of nucleic acids, transcriptional control and genome editing.

Cas9 proteins and guiding features for DNA targeting and genome editing

This invention relates to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays and recombinant nucleic acid constructs encoding Type I-E CASCADE complexes as well as plasmids, retroviruses and bacteriophage comprising the same.

Recombinant type I CRISPR-CAS system

The invention is directed to antibacterial compositions comprising bacteria modified to comprise phasmids engineered to deliver of CRISPR RNAs and methods for their use.

Methods and compositions for delivery of CRISPR based antimicrobials

The present invention is directed to methods and compositions for typing ofbacterial strains, detecting the presence of ain a sample, identifying a strain ofhaving resistance to an invasive foreign genetic element, modifying the resistance of bacteria and archeae to an invasive foreign genetic element, and introducing nicks into or cleaving double stranded DNA for genome editing.

Compositions and methods related to a type-II CRISPR-Cas system in

This invention relates to the use of CRISPR nucleic acids to screen for essential and non-essential genes and expendable genomic islands in bacteria, archaea, algae and/or yeast, to kill bacteria, archaea, algae and/or yeast, to identify the phenotype of a gene or genes, and/or to screen for reduced genome size and/or a gene deletion in bacteria, archaea, algae and/or yeast.

Methods for screening bacteria, archaea, algae, and yeast using CRISPR nucleic acids

The present invention is directed to methods and compositions for genome editing and DNA targeting of proteins.

Methods and compositions for sequence guiding Cas9 targeting

Recombinant type I CRISPR-Cas system

The invention relates to CRISPR sequences found in bifidobacteria and their uses.

Bifidobacteria CRISPR sequences

The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.

Method of modulating cell resistance

Growing community of inventors

Raleigh, NC, United States of America

Rodolphe Barrangou